Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.
Rosh
Joel R
JR
Oliva-Hemker
Maria
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D003657:Decision Making; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008113:Liver Neoplasms / Q000139:chemically induced*; D016399:Lymphoma, T-Cell / Q000139:chemically induced*; D013160:Splenic Neoplasms / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000069285:Infliximab